US-based TransTech Pharma has entered into an agreement with the US Food and Drug Administration Division of Neurology Products, under the special protocol assessment (SPA) process, for design of a single Phase III trial of TTP488 to treat patients with mild Alzheimer’s disease (AD).

SPA from the FDA is a binding agreement that the Phase III trial design, planned execution and statistical analyses are acceptable to support regulatory approval.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The randomised, double-blind, placebo-controlled, multi-centre Phase III trial will compare TTP488 5mg daily with placebo over the course of 18 months of treatment.

"Patient enrolment in the Phase III trial of TTP488 is expected to begin before the end of this year."

Around 800 patients with mild Alzheimer’s disease receiving standard of care (i.e. acetylcholinesterase inhibitors) will be enrolled in the trial.

The trial’s primary efficacy analysis will be based on the changes in ADAS-cog (‘Alzheimer’s Disease Assessment Scale – cognitive subscale’) and CDR-sb (‘Clinical Dementia Rating – sum of boxes’).

See Also:

Patient enrolment in the Phase III trial of TTP488 is expected to begin before the end of this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

TransTech Pharma president and CFO Steve Holcombe said: "We are extremely pleased to receive agreement on the SPA and to have a clear path forward for the submission and regulatory approval of TTP488 for the treatment of patients with mild Alzheimer’s disease."

TTP488 is a new small-molecule, orally active antagonist of the Receptor for Advanced Glycation Endproducts (RAGE).

According to the company, substantial data suggest that RAGE is involved in the pathogenesis of AD, and that sustained Ab interaction with RAGE at the blood-brain barrier (BBB), or in neuronal or microglial cells, is an important element of amyloid plaque formation and chronic neural dysfunction.

The company said that in a double-blind clinical trial where data was collected over 18 months, TTP488 slowed cognitive decline in patients with mild to moderate AD.